Donna Skerrett
Follow
Get notifications in MyBN when activity occurs.
Donna Skerrett
Executive Director / Paradigm Biopharmaceuticals
Donna Skerrett has over 30 years of experience in the pharmaceutical industry, in transfusion medicine, cellular therapy and transplantation.
Dr Skerrett was the director of transfusion medicine and cellular therapy at Weill Cornell Medical Centre in New York from 2004 to 2011, and an associate director of transfusion medicine and director of stem cell facilities at Columbia University's New York-Presbyterian Hospital from 1999 to 2004. She has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989, and a board member of the Alliance for Regenerative Medicine since 2014.
Dr Skerrett joined Paradigm Biopharmaceuticals in September 2019 as chief medical officer, with her primary role to manage the company's clinical development programs across its entire indication pipeline.
Dr Skerrett was the director of transfusion medicine and cellular therapy at Weill Cornell Medical Centre in New York from 2004 to 2011, and an associate director of transfusion medicine and director of stem cell facilities at Columbia University's New York-Presbyterian Hospital from 1999 to 2004. She has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989, and a board member of the Alliance for Regenerative Medicine since 2014.
Dr Skerrett joined Paradigm Biopharmaceuticals in September 2019 as chief medical officer, with her primary role to manage the company's clinical development programs across its entire indication pipeline.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 10th | Arovella Therapeutics | 432% | 110% |
| 39th | Biotron | 184% | 1% |
| 1767th | Spark Infrastructure Group | -72% | -22% |
| 1780th | Paradigm Biopharmaceuticals | -73% | -20% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 832nd |  | Paradigm Biopharmaceuticals | $6.8m |
| 974th | | Arovella Therapeutics | $1.5m |
| 975th | | Biotron | $1.4m |
| 977th | | Spark Infrastructure Group | $1.4m |
| 978th | | Argonaut Resources NL | $1.4m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Executive Director, Paradigm Biopharmaceuticals | 03 Nov 2020 |
